ProPhase Labs, Inc. (PRPH)
USD 0.29
(2.28%)
USD 0.29
(2.28%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.84 Million USD | -3.4% |
| 2022 | 3.97 Million USD | -13.57% |
| 2021 | 4.6 Million USD | 51.37% |
| 2020 | 3.03 Million USD | 108.29% |
| 2019 | 1.45 Million USD | -23.33% |
| 2018 | 1.9 Million USD | 24.3% |
| 2017 | 1.53 Million USD | -44.04% |
| 2016 | 2.73 Million USD | -36.83% |
| 2015 | 4.33 Million USD | 31.56% |
| 2014 | 3.29 Million USD | 30.58% |
| 2013 | 2.52 Million USD | 22.92% |
| 2012 | 2.05 Million USD | -23.7% |
| 2011 | 2.68 Million USD | 59.81% |
| 2010 | 1.68 Million USD | 19.72% |
| 2009 | 1.4 Million USD | -53.18% |
| 2008 | 3 Million USD | -37.63% |
| 2007 | 4.81 Million USD | 12.89% |
| 2006 | 4.26 Million USD | 9.28% |
| 2005 | 3.9 Million USD | 12.89% |
| 2004 | 3.45 Million USD | -7.95% |
| 2003 | 3.75 Million USD | -17.1% |
| 2002 | 4.52 Million USD | -30.44% |
| 2001 | 6.5 Million USD | -5.93% |
| 2000 | 6.91 Million USD | 11.58% |
| 1999 | 6.2 Million USD | -4.62% |
| 1998 | 6.5 Million USD | -15.58% |
| 1997 | 7.7 Million USD | 7600.0% |
| 1996 | 100 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 3.86 Million USD | 2.9% |
| 2024 Q1 | 3.75 Million USD | -2.16% |
| 2023 Q2 | 3.62 Million USD | -15.96% |
| 2023 Q4 | 3.84 Million USD | -24.0% |
| 2023 Q1 | 4.31 Million USD | 8.43% |
| 2023 FY | 3.84 Million USD | -3.4% |
| 2023 Q3 | 5.05 Million USD | 39.5% |
| 2022 Q4 | 3.97 Million USD | -19.06% |
| 2022 FY | 3.97 Million USD | -13.57% |
| 2022 Q3 | 4.91 Million USD | 8.94% |
| 2022 Q2 | 4.5 Million USD | -3.65% |
| 2022 Q1 | 4.68 Million USD | 1.74% |
| 2021 Q1 | 16.02 Million USD | 427.34% |
| 2021 FY | 4.6 Million USD | 51.37% |
| 2021 Q4 | 4.6 Million USD | -45.95% |
| 2021 Q3 | 8.51 Million USD | -43.9% |
| 2021 Q2 | 15.16 Million USD | -5.35% |
| 2020 Q1 | 1.7 Million USD | 16.72% |
| 2020 Q3 | 2.13 Million USD | 4.45% |
| 2020 Q4 | 3.03 Million USD | 42.14% |
| 2020 FY | 3.03 Million USD | 108.29% |
| 2020 Q2 | 2.04 Million USD | 20.2% |
| 2019 Q2 | 2.02 Million USD | 25.76% |
| 2019 Q1 | 1.61 Million USD | -15.34% |
| 2019 Q3 | 1.88 Million USD | -6.91% |
| 2019 Q4 | 1.45 Million USD | -22.64% |
| 2019 FY | 1.45 Million USD | -23.33% |
| 2018 Q3 | 2.71 Million USD | 13.87% |
| 2018 Q2 | 2.38 Million USD | 18.71% |
| 2018 Q1 | 2.01 Million USD | 31.29% |
| 2018 Q4 | 1.9 Million USD | -29.96% |
| 2018 FY | 1.9 Million USD | 24.3% |
| 2017 Q3 | 1.99 Million USD | 1.32% |
| 2017 FY | 1.53 Million USD | -44.04% |
| 2017 Q2 | 1.96 Million USD | -8.77% |
| 2017 Q1 | 2.15 Million USD | -21.24% |
| 2017 Q4 | 1.53 Million USD | -23.14% |
| 2016 Q2 | 4.34 Million USD | 6.8% |
| 2016 Q4 | 2.73 Million USD | -34.83% |
| 2016 Q3 | 4.19 Million USD | -3.47% |
| 2016 FY | 2.73 Million USD | -36.83% |
| 2016 Q1 | 4.07 Million USD | -5.98% |
| 2015 Q1 | 3.27 Million USD | -0.46% |
| 2015 FY | 4.33 Million USD | 31.56% |
| 2015 Q4 | 4.33 Million USD | -11.45% |
| 2015 Q3 | 4.89 Million USD | 32.01% |
| 2015 Q2 | 3.7 Million USD | 13.06% |
| 2014 Q4 | 3.29 Million USD | -21.24% |
| 2014 Q2 | 3.24 Million USD | 46.84% |
| 2014 Q1 | 2.21 Million USD | -12.26% |
| 2014 Q3 | 4.18 Million USD | 28.69% |
| 2014 FY | 3.29 Million USD | 30.58% |
| 2013 Q4 | 2.52 Million USD | -22.98% |
| 2013 Q3 | 3.27 Million USD | -0.49% |
| 2013 Q2 | 3.28 Million USD | 53.19% |
| 2013 Q1 | 2.14 Million USD | 4.68% |
| 2013 FY | 2.52 Million USD | 22.92% |
| 2012 FY | 2.05 Million USD | -23.7% |
| 2012 Q1 | 2.61 Million USD | -2.86% |
| 2012 Q2 | 3.14 Million USD | 20.3% |
| 2012 Q3 | 3.41 Million USD | 8.69% |
| 2012 Q4 | 2.05 Million USD | -39.92% |
| 2011 FY | 2.68 Million USD | 59.81% |
| 2011 Q1 | 1.34 Million USD | -20.04% |
| 2011 Q2 | 1.59 Million USD | 18.51% |
| 2011 Q3 | 3.51 Million USD | 120.7% |
| 2011 Q4 | 2.68 Million USD | -23.59% |
| 2010 Q2 | 1.15 Million USD | 1.68% |
| 2010 Q3 | 2.36 Million USD | 105.38% |
| 2010 Q1 | 1.13 Million USD | -19.29% |
| 2010 Q4 | 1.68 Million USD | -28.97% |
| 2010 FY | 1.68 Million USD | 19.72% |
| 2009 Q4 | 1.4 Million USD | -55.82% |
| 2009 Q2 | 3.09 Million USD | -4.5% |
| 2009 Q1 | 3.24 Million USD | 8.15% |
| 2009 Q3 | 3.18 Million USD | 2.6% |
| 2009 FY | 1.4 Million USD | -53.18% |
| 2008 Q3 | 5.07 Million USD | 9.8% |
| 2008 Q1 | 4.31 Million USD | -10.37% |
| 2008 Q2 | 4.62 Million USD | 7.16% |
| 2008 FY | 3 Million USD | -37.63% |
| 2008 Q4 | 3 Million USD | -40.85% |
| 2007 Q3 | 5.8 Million USD | -1.26% |
| 2007 FY | 4.81 Million USD | 12.89% |
| 2007 Q2 | 5.87 Million USD | 41.15% |
| 2007 Q1 | 4.16 Million USD | -2.31% |
| 2007 Q4 | 4.81 Million USD | -17.09% |
| 2006 Q2 | 4.79 Million USD | 13.45% |
| 2006 Q3 | 5.04 Million USD | 5.12% |
| 2006 Q4 | 4.26 Million USD | -15.47% |
| 2006 FY | 4.26 Million USD | 9.28% |
| 2006 Q1 | 4.22 Million USD | 8.4% |
| 2005 FY | 3.9 Million USD | 12.89% |
| 2005 Q4 | 3.9 Million USD | -2.44% |
| 2005 Q3 | 3.99 Million USD | 6.29% |
| 2005 Q2 | 3.76 Million USD | 10.05% |
| 2005 Q1 | 3.41 Million USD | -1.08% |
| 2004 Q4 | 3.45 Million USD | -19.09% |
| 2004 Q2 | 4.29 Million USD | 8.6% |
| 2004 Q1 | 3.95 Million USD | 5.37% |
| 2004 Q3 | 4.26 Million USD | -0.58% |
| 2004 FY | 3.45 Million USD | -7.95% |
| 2003 Q3 | 4.52 Million USD | -0.44% |
| 2003 Q1 | 4.4 Million USD | -2.6% |
| 2003 FY | 3.75 Million USD | -17.1% |
| 2003 Q2 | 4.54 Million USD | 3.12% |
| 2003 Q4 | 3.75 Million USD | -17.08% |
| 2002 Q1 | 5.97 Million USD | -8.17% |
| 2002 Q4 | 4.52 Million USD | -28.67% |
| 2002 Q3 | 6.34 Million USD | -4.14% |
| 2002 Q2 | 6.62 Million USD | 10.78% |
| 2002 FY | 4.52 Million USD | -30.44% |
| 2001 Q1 | 7.63 Million USD | 10.34% |
| 2001 Q2 | 7.33 Million USD | -3.88% |
| 2001 Q3 | 7 Million USD | -4.52% |
| 2001 Q4 | 6.5 Million USD | -7.11% |
| 2001 FY | 6.5 Million USD | -5.93% |
| 2000 Q4 | 6.91 Million USD | -1.53% |
| 2000 Q2 | 6.67 Million USD | 10.86% |
| 2000 Q1 | 6.01 Million USD | -2.94% |
| 2000 FY | 6.91 Million USD | 11.58% |
| 2000 Q3 | 7.02 Million USD | 5.32% |
| 1999 Q4 | 6.2 Million USD | -12.68% |
| 1999 Q3 | 7.1 Million USD | 0.0% |
| 1999 Q2 | 7.1 Million USD | 5.97% |
| 1999 FY | 6.2 Million USD | -4.62% |
| 1999 Q1 | 6.7 Million USD | 3.08% |
| 1998 Q2 | 8.5 Million USD | 16.44% |
| 1998 Q1 | 7.3 Million USD | -5.19% |
| 1998 Q3 | 7.9 Million USD | -7.06% |
| 1998 FY | 6.5 Million USD | -15.58% |
| 1998 Q4 | 6.5 Million USD | -17.72% |
| 1997 Q3 | 9.9 Million USD | 33.78% |
| 1997 Q1 | 800 Thousand USD | 166.67% |
| 1997 FY | 7.7 Million USD | 7600.0% |
| 1997 Q2 | 7.4 Million USD | 825.0% |
| 1997 Q4 | 7.7 Million USD | -22.22% |
| 1996 Q4 | 300 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 88.12% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -374.34% |
| Embecta Corp. | 152.1 Million USD | 97.475% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 96.319% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 33.022% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Journey Medical Corporation | 10.2 Million USD | 62.365% |
| Safety Shot Inc | 1.86 Million USD | -105.44% |
| Alpha Teknova, Inc. | 11.59 Million USD | 66.871% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 96.83 Million USD | 96.033% |
| Alvotech | 74.43 Million USD | 94.84% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 96.546% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 43.256% |
| Cosmos Health Inc. | 4.78 Million USD | 19.796% |
| Dynavax Technologies Corporation | 53.29 Million USD | 92.792% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 94.147% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 67.022% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 33.022% |
| Theratechnologies Inc. | 6.06 Million USD | 36.68% |
| Harrow Health, Inc. | 10.86 Million USD | 64.654% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -41.265% |
| Biofrontera Inc. | 10.9 Million USD | 64.787% |
| DURECT Corporation | 2.21 Million USD | -73.096% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 95.038% |
| Cronos Group Inc. | 30.33 Million USD | 87.34% |
| OptiNose, Inc. | 8.05 Million USD | 52.298% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -384099900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 32.603% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 86.405% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -43.476% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 16.67% |
| Radius Health, Inc. | 278.64 Million USD | 98.622% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -14.888% |
| Phibro Animal Health Corporation | 265.91 Million USD | 98.556% |
| Procaps Group S.A. | 96.83 Million USD | 96.033% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.889% |
| Rockwell Medical, Inc. | 5.87 Million USD | 34.577% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 69.596% |
| SIGA Technologies, Inc. | 64.21 Million USD | 94.019% |
| Tilray Brands, Inc. | 252.08 Million USD | 98.476% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 90.392% |
| Shineco, Inc. | 1.58 Million USD | -141.797% |
| PetIQ, Inc. | 159.3 Million USD | 97.589% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 2614.105% |
| Incannex Healthcare Limited | -10.01 Million USD | 138.352% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 89.971% |
| Alimera Sciences, Inc. | 1.87 Million USD | -104.417% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 89.808% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -138.514% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 14.321% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -1410.112% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 62.996% |
| Hempacco Co., Inc. | 2.54 Million USD | -51.064% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 94.84% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 91.963% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 94.001% |
| Currenc Group, Inc. | 732.91 Thousand USD | -424.075% |
| Kamada Ltd. | 87.74 Million USD | 95.623% |
| Indivior PLC | 141.79 Million USD | 97.291% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -697.153% |
| Flora Growth Corp. | 8.5 Million USD | 54.854% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -1410.112% |
| Evolus, Inc. | 10.99 Million USD | 65.075% |
| HUTCHMED (China) Limited | 50.25 Million USD | 92.357% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 96.371% |
| Akanda Corp. | 1.28 Million USD | -198.471% |